Gastroenterology > Inflammatory Bowel disease > personalised medicine; biomarkers; multi-omics

Inflammatory bowel diseases (IBD) are complex diseases resulting from the combination of multiple etiological factors, and present major challenges in diagnosis, classification and management. Current treatment strategies are applied in an indiscriminate fashion, though anti-inflammatory drugs only benefit a limited number of patients (ceiling of 30-40%) and therefore leaving large margins for improvement. This “one measure does not fit all” situation has spurred the notion that IBD therapy should be tailored to the individual patient. During recent years, my research has mainly aimed to improve outcomes and personalise healthcare in IBD. On a local and international level, I have contributed to the IBD biomarker field by founding collaborative research initiatives to foster IBD precision medicine. In addition, I have generated and validated potential and promising biomarkers using multi-omic approaches using local datasets, as well as data generated in randomised clinical trials. Next steps include additional discovery, validation and ultimately implementation of promising biomarkers in daily clinical practice to improve IBD patient care.

Keywords:inflammatory bowel disease, precision medicine, biomarker

Disciplines:Gastro-enterology